COMP <GO>
TVTX vs PTCT // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Travere Therapeutics Inc. (NASDAQ) VS. PTC Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TVTX 1
— PTCT 10
■ METRIC PARITY
LAST: $49.26 (-2.24%) • MKT CAP: $4.75B
options-implied-move
—
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. PTCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | PTCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 85.00% | -98.00 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.33% | 13.05% | -12.72 | PTCT | /fcf-yield <GO> |
| Operating Margin | -12.80% | 50.10% | -62.90 | PTCT | /operating-margins <GO> |
| Net Profit Margin | -5.20% | 39.50% | -44.70 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | 114.50% | -4.00 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.44 | 1.73 | +1.71 | TVTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.8 | 43.2 | -7.40 | PTCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 6.6x | +11.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.75B | $5.01B | -$260.3M | PTCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | PTCT REV | TVTX GROSS % | PTCT GROSS % | TVTX FCF | PTCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $1.73B | 97.9% | — | $15.7M | $702.3M |
| FY 2024 | $233.2M | $806.8M | 96.7% | — | -$248.0M | -$114.2M |
| FY 2023 | $145.2M | $937.8M | — | — | -$286.6M | -$200.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
PTCT // BETA 1.15